209 related articles for article (PubMed ID: 9687402)
1. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae.
Brenwald NP; Gill MJ; Wise R
Antimicrob Agents Chemother; 1998 Aug; 42(8):2032-5. PubMed ID: 9687402
[TBL] [Abstract][Full Text] [Related]
2. Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae.
Piddock LJ; Johnson MM; Simjee S; Pumbwe L
Antimicrob Agents Chemother; 2002 Mar; 46(3):808-12. PubMed ID: 11850265
[TBL] [Abstract][Full Text] [Related]
3. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
[TBL] [Abstract][Full Text] [Related]
4. Apparent involvement of a multidrug transporter in the fluoroquinolone resistance of Streptococcus pneumoniae.
Baranova NN; Neyfakh AA
Antimicrob Agents Chemother; 1997 Jun; 41(6):1396-8. PubMed ID: 9174208
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy.
Montanari MP; Tili E; Cochetti I; Mingoia M; Manzin A; Varaldo PE
Microb Drug Resist; 2004; 10(3):209-17. PubMed ID: 15383164
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of older and newer fluoroquinolones against efflux-mediated high-level ciprofloxacin-resistant Streptococcus pneumoniae.
Daporta MT; Muñoz Bellido JL; Guirao GY; Hernández MS; García-Rodríguez JA
Int J Antimicrob Agents; 2004 Aug; 24(2):185-7. PubMed ID: 15288320
[TBL] [Abstract][Full Text] [Related]
7. Nonmolecular test for detection of low-level resistance to fluoroquinolones in Streptococcus pneumoniae.
Varon E; Houssaye S; Grondin S; Gutmann L;
Antimicrob Agents Chemother; 2006 Feb; 50(2):572-9. PubMed ID: 16436712
[TBL] [Abstract][Full Text] [Related]
8. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae.
Broskey J; Coleman K; Gwynn MN; McCloskey L; Traini C; Voelker L; Warren R
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():95-9. PubMed ID: 10824039
[TBL] [Abstract][Full Text] [Related]
9. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.
Weigel LM; Anderson GJ; Facklam RR; Tenover FC
Antimicrob Agents Chemother; 2001 Dec; 45(12):3517-23. PubMed ID: 11709333
[TBL] [Abstract][Full Text] [Related]
10. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
[TBL] [Abstract][Full Text] [Related]
11. Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae.
Zeller V; Janoir C; Kitzis MD; Gutmann L; Moreau NJ
Antimicrob Agents Chemother; 1997 Sep; 41(9):1973-8. PubMed ID: 9303396
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
[TBL] [Abstract][Full Text] [Related]
13. Evidence for efflux pumps, other than PmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae.
Brenwald NP; Appelbaum P; Davies T; Gill MJ
Clin Microbiol Infect; 2003 Feb; 9(2):140-3. PubMed ID: 12588335
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic characterization of efflux and topoisomerase IV-mediated fluoroquinolone resistance in Streptococcus pneumoniae.
Madaras-Kelly KJ; Daniels C; Hegbloom M; Thompson M
J Antimicrob Chemother; 2002 Aug; 50(2):211-8. PubMed ID: 12161401
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of fluoroquinolone resistance: an update 1994-1998.
Piddock LJ
Drugs; 1999; 58 Suppl 2():11-8. PubMed ID: 10553699
[TBL] [Abstract][Full Text] [Related]
16. Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones.
Ho PL; Yam WC; Que TL; Tsang DN; Seto WH; Ng TK; Ng WS
J Antimicrob Chemother; 2001 May; 47(5):655-8. PubMed ID: 11328779
[TBL] [Abstract][Full Text] [Related]
17. Fluoroquinolone resistance in atypical pneumococci and oral streptococci: evidence of horizontal gene transfer of fluoroquinolone resistance determinants from Streptococcus pneumoniae.
Ip M; Chau SS; Chi F; Tang J; Chan PK
Antimicrob Agents Chemother; 2007 Aug; 51(8):2690-700. PubMed ID: 17548487
[TBL] [Abstract][Full Text] [Related]
18. Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756.
Hartman-Neumann S; DenBleyker K; Pelosi LA; Lawrence LE; Barrett JF; Dougherty TJ
Antimicrob Agents Chemother; 2001 Oct; 45(10):2865-70. PubMed ID: 11557482
[TBL] [Abstract][Full Text] [Related]
19. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
[TBL] [Abstract][Full Text] [Related]
20. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
Gootz TD; Zaniewski R; Haskell S; Schmieder B; Tankovic J; Girard D; Courvalin P; Polzer RJ
Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
